Glaxo Smith Kline’s decision to discontinue a popular children’s asthma inhaler, Flovent, more than two years ago has caused ...

Move comes 2 years after controversial exit of brand-name product ...

Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...

Three sailors on the USS Gerald R Ford received medical treatment after the fire, and dozens suffered smoke inhalation - ...

For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not ...

Nonclinical factors are more likely to drive discontinuation of biologic therapy for patients with severe asthma.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 AAAAI Annual Meeting.

Asthma and chronic obstructive pulmonary disease patients will receive better care closer to home under a landmark £10million partnership Care for ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF) presented research on Sunday demonstrating its diagnostic platform’s ability to identify antibody drug receptors in sputum for asthma ...

A retrospective cohort study of 210,000 pediatric patients showed ICS therapy did not elevate the risk for pediatric fractures.

Maggie Hassan. The setup forced many users to pay higher prices and allowed the British drugmaker to avoid paying Medicaid ...

MILWAUKEE, Feb. 16, 2026 /PRNewswire/ -- Immune checkpoint inhibitors (ICIs) were associated with modest protective effects for patients with asthma, according to new research being presented at the ...